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Although the use of tenofovir alafenamide (TAF), a new prod-
rug of tenofovir, was safe and efficacious in clinical trials, real-
world data from multimorbid individuals are scarce. Among 
10 persons living with HIV with previous tenofovir disoproxil 
fumarate–induced nephrotoxicity, renal function remained 
stable, and proteinuria decreased in several patients after the 
switch to TAF.
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As HIV-infected populations are aging, noncommunicable dis-
eases and long-term toxicity of antiretroviral therapy (ART) 
emerge as important determinants of HIV clinical management 
[1]. The use of tenofovir disoproxil fumarate (TDF) is associated 
with a loss in bone mineral density (BMD) and the development 
of proximal tubular renal dysfunction, with the potential pro-
gression to Fanconi syndrome characterized by phosphaturia, 
glucosuria, tubular proteinuria, and proximal renal tubular acid-
osis [2–5]. Tenofovir alafenamide (TAF), a new tenofovir (TFV) 
prodrug, leads to reduced TFV plasma levels, while maintaining 
high intracellular TFV concentrations in target cells, decreasing 
the risk for renal toxicity. TAF offers a safe and effective thera-
peutic option for both treatment-naïve and -experienced HIV/
hepatitis B virus (HBV)–coinfected [6] and HIV-monoinfected 
patients [7, 8]. In patients with renal impairment, the prevalence 
of significant proteinuria decreased from 42% to 11% 1 year after 
the switch to TAF [9]. However, despite improvements in renal 
tubular markers and BMD with TAF, no study has shown a rel-
evant improvement in glomerular filtration. Although serum 
lipids improve with TDF, this is not the case with TAF [10]. In 
a recent meta-analysis, TAF was associated with a 1% greater 
risk of being started on lipid-lowering therapy over 48 weeks of 
follow-up [11]. However, these changes in lipid profile have not 
been linked to an elevated cardiovascular risk to date.
Despite recent evidence on the safety and efficacy of TAF 
in large clinical trials, real-world safety data from cohorts of 
heavily treatment-experienced, multimorbid patients are scarce 
[12–14]. We present the first cases of persons living with HIV 
(PLHIV) with TDF-associated renal toxicity in whom TDF was 
replaced by TAF in a single center in Switzerland.
ILLUSTRATIVE CASE
In 2007, a 54-year-old HIV/HBV/hepatitis C virus (HCV)-co-
infected woman previously exposed to all antiretroviral drug 
classes, developed phosphaturia with hypophosphatemia, 
worsening estimated glomerular filtration rate (eGFR) and 
osteoporosis on a TDF-containing regimen (Table  1, patient 
1, and Figure 1). After TDF was stopped, she remained viro-
logically suppressed on etravirine, ritonavir-boosted daruna-
vir and raltegravir, but her medical history was complicated 
by recurrent cerebral vasculitis and severe osteoporosis. After 
TDF was stopped, HBV infection was treated with lamivu-
dine monotherapy for 4  years, until viral failure occurred, 
with documented resistance to lamivudine and entecavir 
(L80V, L180M, M204I, 184S). Therefore, TDF was reintro-
duced in 2014, but had to be stopped shortly thereafter due 
to acute renal failure (eGFR drop from 71 to 41 mL/min/1.72 
m2) with proteinuria, phosphaturia, hypophosphatemia and 
hypokalemia, suggesting generalized proximal tubular dys-
function. In the context of the worsening cerebral vasculitis, 
a potential extrahepatic manifestation of HBV and HCV, F/
TAF was initiated and the HBV viral load decreased from 9.39 
log10 to 2.42 log10 copies/mL over 32  months. Incomplete 
virological response after years of TDF treatment has been 
reported in previous studies of HIV/HBV-coinfected patients 
[15, 16]. Concurrent HCV infection was successfully treated 
with sofosbuvir and ledipasvir. Despite a minimal decline 
in kidney function in the first two weeks after the introduc-
tion of TAF, it remained stable thereafter and the proteinuria 
resolved. Furthermore, no recurrence of the cerebral vasculitis 
was observed. In summary, the introduction of TAF in this 
patient with prior severe TDF toxicity was safe and offered 
treatment for her multidrug-resistant HBV infection.
METHODS
We included all PLHIV who switched to a TAF-containing reg-
imen due to prior TDF-induced renal toxicity with a follow-up 
time on TAF of at least 12 months at Bern University Hospital, 
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a site of the Swiss HIV Cohort Study (SHCS; www.shcs.ch). 
Medical charts were reviewed, and clinical and laboratory 
information, including HIV and HBV viral loads (VLs), serum 
lipid profile (total cholesterol, high-density lipoprotein [HDL], 
low-density lipoprotein [LDL], triglycerides), renal function 
(inorganic phosphate as well as creatinine and protein in serum 
and urine to calculate the urine protein to creatinine ratio 
[UPCR]), and results from bone mineral density (BMD) test-
ing, was retrieved. Estimated glomerular filtration rate (eGFR) 
was estimated using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation, and significant proteinuria 
was defined as a UPCR of >20  mg/mmol. Generalized prox-
imal tubular dysfunction (Fanconi syndrome) was defined as 
the presence of renal glucosuria, proteinuria, and phosphaturia 
with concomitant hypophosphatemia, with or without signs 
of proximal renal tubular acidosis. No statistical analysis was 
performed due to the small sample size. All patients were par-
ticipants of the SHCS and signed an informed consent to partic-
ipate. Before licencing of F/TAF in Switzerland in May 2017, the 
drug was obtained through a compassionate use program from 
Gilead Sciences. For each patient, approval by the Swiss Medical 
Agency (Swissmedic; www.swissmedic.ch) was obtained.
RESULTS
At the time of data analysis, 17 patients had switched from TDF 
to TAF. Of these, 10 patients with prior contraindications to TDF 
had at least 1 year of follow-up and were included in this analysis. 
The median age (interquartile range [IQR]) was 55 (53–70) years 
(Table 1). At the time of switch to TAF, all patients had a suppressed 
HIV VL, and the median CD4 cell count (IQR) was 688 (437–828) 
cells/µL. Participants were heavily treatment-experienced (median 
time on ART, 19 years) and had numerous changes of drug classes 
due to virological failure, side effects, and potential long-term tox-
icity. Nine patients had significant, mostly cardiovascular comor-
bidities, and 7 had more than 3 comedications. Osteoporosis was 
documented in 4 patients at baseline, and osteopenia was docu-
mented in 3. Three patients had concomitant chronic HBV infec-
tion, and 2 had a chronic HCV infection. The reason for switching 
to TAF was the presence of Fanconi syndrome (2/10), proximal renal 
tubulopathy (elevated phosphate excretion fraction (FE-Pi) with or 
without proteinuria) (7/10), and progressive chronic kidney disease 
with proteinuria (1/10). Six patients were directly switched from 
TDF to TAF, whereas in 4 patients TDF had to be stopped earlier 
(median, 13 months before TAF initiation). In the 3 patients with 
HBV coinfection, TAF was the only HBV active drug: 2 individuals 
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mide; TDF, tenofovir disoproxil fumarate.
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/5/11/ofy275/5144205 by E-Library Insel user on 06 D
ecem
ber 2018
4 • OFID • BRIEF REPORT
had intermediate resistance to entecavir (L180M, M204V), and 1 
was fully resistant (L80V, L180M, M204I, 184S). All patients had 
impaired renal function (median eGFR [IQR], 61 [52–71] mL/min). 
Eight had a phosphate excretion fraction (FE-Pi) >20%, of whom 
7 had hypophosphatemia. Proteinuria was found in 7 patients (5/6 
currently on TDF), and the median UPCR (IQR) was 28 (22–32) 
mg/mmol.
During follow-up, patients remained HIV-suppressed, except 
for a single blip (69 copies/mL) in 1 patient, and HBV VL was 
undetectable in 2 of 3 coinfected patients. In the third patient, 
HBV VL decreased but remained detectable (see the case report 
above). Renal glomerular function remained stable, with a 
median change in eGFR (IQR) at 12 months of –0.5 ( –3 to +3) 
mL/min (Figure 2A). No Fanconi syndrome or other acute kid-
ney injury was observed during the first year of TAF. Only small 
changes in tubular markers were seen (Figure  2C), and the 
proportion of patients with a significant proteinuria (>20 mg/
mmol) decreased from 70% to 30% (Figure 2B). Consequently, 
CKD stage improved in 4 of 10 patients (3 of them directly 
switched from TDF to TAF; for the fourth patient, see the case 
report above). Nearly all patients experienced a rise in serum 
LDL (median level at switch: 2.5 mmol/L [96.78 mg/dl], at 1 
year: 3.29 mmol/L [127.22 mg/dL]), total cholesterol/HDL ratio 
(median ratio at switch: 4.45, at 1 year: 5.55) and serum tri-
glycerides (median level at switch: 1.7 mmol/L [65.73 mg/dL], 
at 1 year: 2.5 mmol/L [96.78 mg/dL]) during the study period 
(Figure 2D–F). There were no adverse events attributed to TAF, 
and no cardiovascular events occurred. One patient died during 
follow-up for reasons not related to the ART regimen.
DISCUSSION
In our case series of 10 multimorbid patients switched to 
TAF with prior TDF-associated kidney injury, renal function 
remained stable over the first year, whereas proteinuria improved 
in several patients. Our findings support the use of TAF in HIV-
monoinfected and HIV/HBV-coinfected patients with severe 
TDF-related toxicity, but prospective, long-term studies in simi-
lar populations are needed to confirm our findings.
The reversibility of TDF-associated kidney injury remains 
uncertain: recovery of kidney function (eGFR) after TDF cessa-
tion is generally reported in patients with acute, but not chronic, 
kidney disease [17–19]. Changes in eGFR usually occur late 
in the context of TDF-associated proximal tubulopathy and 
might represent irreversible injury [17, 18]. Importantly, as 
many other comorbidities contribute to CKD (eg, hyperten-
sion, dyslipidemia), the interruption of TDF alone might be 
insufficient to improve renal function. Nevertheless, the pro-
portion of patients with significant proteinuria dropped from 
70% at baseline to 30% after 1 year of TAF in our study. As a 
consequence, CKD stage improved in 4 of 10 patients, which 
is more than previously reported [9]. In 1 patient (see the case 
report) who initiated TAF years after TDF cessation, protein-
uria resolved with concomitant HCV treatment, emphasizing 
the importance of the elimination of other factors potentially 
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contributing to renal injury. Although 2-year follow-up data 
from a study of patients who switched to TAF with prior renal 
impairment were reassuring [20, 21], its long-term safety profile 
remains uncertain. Interestingly, 2 cases of acute nephrotoxicity 
in cirrhotic patients receiving an ART regimen including TAF 
and cobicistat were recently reported [22, 23]. Although these 
findings suggest that TAF could potentially be associated with 
the occurrence of acute nephropathy, no patient in our series 
developed renal injury despite their high-risk profile.
The lipid profile worsened in most patients after the switch to 
TAF. However, the impact of this change on cardiovascular risk in 
these multimorbid patients remains unclear. Surprisingly, the effect 
was also seen in 3/4 patients who had interrupted TDF months 
before the introduction of TAF, which argues against the protective 
effect of TDF as the only cause for the changes in lipid values.
In conclusion, in this case series of multimorbid HIV-infected 
patients with contraindications to TDF, TAF was well tolerated 
and led to a reduction in proteinuria in several patients. We 
observed no improvement in glomerular function and no con-
sistent changes in other tubular markers during the first year of 
therapy. Long-term effects of TAF on renal function and BMD, 
as well as on plasma lipids, need to be evaluated in dedicated 
long-term prospective studies.
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